Cubist announced that Sivextro (tedizolid phosphate) is now available for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) in both the IV and oral formulations.
Sivextro is a novel oxazolidinone with in vitro activity against clinically significant susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Tedizolid phosphate, the prodrug of tedizolid, binds to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid inhibits bacterial protein synthesis through a mechanism different from other non-oxazolidinone antibiotics.
Further clinical trials are under way for the potential use of Sivextro in the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Sivextro is available as 200mg strength tablets in 30-count bottles and 6-tablet blister packs, as well as 200mg single-dose vials in 10-count packages.
For more information call (844) CUBIST-CARES or visit Sivextro.com.